SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Olsson Daniel S 1983 ) "

Sökning: WFRF:(Olsson Daniel S 1983 )

  • Resultat 21-30 av 37
  • Föregående 12[3]4Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
21.
  • Hammarstrand, Casper, 1990-, et al. (författare)
  • Higher glucocorticoid replacement doses are associated with increased mortality in patients with pituitary adenoma
  • 2017
  • Ingår i: European Journal of Endocrinology. - 1479-683X. ; 177:3, s. 251-256
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: Patients with secondary adrenal insufficiency (AI) have an excess mortality. The objective was to investigate the impact of the daily glucocorticoid replacement dose on mortality in patients with hypopituitarism due to non-functioning pituitary adenoma (NFPA). METHODS: Patients with NFPA were followed between years 1997 and 2014 and cross-referenced with the National Swedish Death Register. Standardized mortality ratio (SMR) was calculated with the general population as reference and Cox-regression was used to analyse the mortality. RESULTS: The analysis included 392 patients (140 women) with NFPA. Mean ± s.d. age at diagnosis was 58.7 ± 14.6 years and mean follow-up was 12.7 ± 7.2 years. AI was present in 193 patients, receiving a mean daily hydrocortisone equivalent (HCeq) dose of 20 ± 6 mg. SMR (95% confidence interval (CI)) for patients with AI was similar to that for patients without, 0.88 (0.68-1.12) and 0.87 (0.63-1.18) respectively. SMR was higher for patients with a daily HCeq dose of >20 mg (1.42 (0.88-2.17)) than that in patients with a daily HCeq dose of 20 mg (0.71 (0.49-0.99)), P = 0.017. In a Cox-regression analysis, a daily HCeq dose of >20 mg was independently associated with a higher mortality (HR: 1.88 (1.06-3.33)). Patients with daily HCeq doses of ≤20 mg had a mortality risk comparable to patients without glucocorticoid replacement and to the general population. CONCLUSION: Patients with NFPA and AI receiving more than 20 mg HCeq per day have an increased mortality. Our data also show that mortality in patients substituted with 20 mg HCeq per day or less is not increased. © 2017 European Society of Endocrinology.
  •  
22.
  • Jakobsson, Sofie, 1968-, et al. (författare)
  • Extended Support Within a Person-Centered Practice After Surgery for Patients With Pituitary Tumors: Protocol for a Quasiexperimental Study.
  • 2020
  • Ingår i: JMIR research protocols. - 1929-0748. ; 9:7
  • Tidskriftsartikel (refereegranskat)abstract
    • Patients with pituitary tumors often live with lifelong consequences of their disease. Treatment options include surgery, radiotherapy, and medical therapy. Symptoms associated with the tumor or its treatment affect several areas of life. Patients need to adhere to long-term contact with both specialist and general health care providers due to the disease, complex treatments, and associated morbidity. The first year after pituitary surgery constitutes an important time period, with medical evaluations after surgery and decisions on hormonal substitution. The development and evaluation of extended patient support during this time are limited.The aim of this study is to evaluate whether support within a person-centered care practice increases wellbeing for patients with pituitary tumors. Our main hypothesis is that the extended support will result in increased psychological wellbeing compared with the support given within standard of care. Secondary objectives are to evaluate whether the extended support, compared with standard care, will result in (1) better health status, (2) less fatigue, (3) higher satisfaction with care, (4) higher self-efficacy, (5) increased person-centered content in care documentation, and (6) sustained patient safety.Within a quasiexperimental design, patients diagnosed with a pituitary tumor planned for neurosurgery are consecutively included in a pretest-posttest study performed at a specialist endocrine clinic. The control group receives standard of care after surgery, and the interventional group receives structured patient support for 1 year after surgery based on person-centeredness covering self-management support, accessibility, and continuity. A total of 90 patients are targeted for each group.Recruitment into the control group was performed between Q3 2015 and Q4 2017. Recruitment into the intervention group started in Q4 2017 and is ongoing until Q4 2020. The study is conducted according to the Declaration of Helsinki, and the protocol has received approval from a regional ethical review board.This study entails an extensive intervention constructed in collaboration between clinicians, patients, and researchers that acknowledges accessibility, continuity, and self-management support within person-centeredness. The study has the potential to compare standard care to person-centered practice adapted specifically for patients with pituitary tumors and evaluated with a combination of patient-reported outcomes and patient-reported experience measures. Following the results, the person-centered practice may also become a useful model to further develop and explore person-centered care for patients with other rare, lifelong conditions.Researchweb.org. https://www.researchweb.org/is/sverige/project/161671.DERR1-10.2196/17697.
  •  
23.
  • Jakobsson Ung, Eva, 1960-, et al. (författare)
  • The pre- and postoperative illness trajectory in patients with pituitary tumours.
  • 2019
  • Ingår i: Endocrine connections. - 2049-3614. ; 8:7, s. 878-886
  • Tidskriftsartikel (refereegranskat)abstract
    • Experiences and need of support during surgery and start of replacement therapy in patients with pituitary tumours are highly unknown. This study therefore aimed at exploring patient experiences during pre- and postoperative care and recovery after pituitary surgery in patients with a pituitary tumour.Within a qualitative study design, 16 consecutive patients who underwent surgery for pituitary tumours were repeatedly interviewed. In total 42 interviews were performed before and after surgery. Analysis was performed using qualitative interpretation.Suffering a pituitary tumour was overwhelming for many patients and struggling with existential issues was common. Patients expressed loneliness and vulnerability before and after surgery. How professionals handled information in connection with diagnosis greatly affected the patients. Other patients with the same diagnosis were experienced as the greatest support. Normalisation of bodily symptoms and relationships with others were reported during postoperative recovery. However, a fear that the tumour would return was present.Patients with pituitary tumours need structured support, including peer support, which acknowledges physical, cognitive as well as emotional and existential concerns. Information related to diagnosis and surgery should be adapted in relation to the loneliness and the existential seriousness of the situation. Care and support for patients with pituitary tumours should preferably be organised based on continuity and an unbroken care pathway from the first pre-operative evaluation through to post-operative care and the start of a life-long endocrine treatment and tumour surveillance.
  •  
24.
  • Kousoula, Konstantina, et al. (författare)
  • The impact of adjustments to the diagnostic criteria for biochemical remission in surgically treated patients with acromegaly
  • 2017
  • Ingår i: Growth Hormone and IGF Research. - 1096-6374. ; 36, s. 16-21
  • Tidskriftsartikel (refereegranskat)abstract
    • Background The suggested criteria for biochemical remission in patients treated for acromegaly were recently modified. The aim of this project was to study to what extent this modification influences remission rates. Design, patients and methods This was a retrospective study of 55 consecutive patients [29 men; median age 47 years (interquartile range 38–68)] diagnosed with acromegaly between 2003 and 2014. After treatment serum IGF-I and/or GH was measured according to a standardized protocol. The biochemical remission status was defined according to the clinical guidelines from 2010 and2014. Results Out of 55 patients, 44 patients were primarily operated. Of these, 33 (75%) were evaluated 3–12 months postoperatively by measuring serum IGF-I and GH during an oral glucose tolerance test. According to the 2010 guidelines, 11 patients (33%) were in biochemical remission, 15 patients (46%) were not and 7 patients (21%) had discordant results (normal IGF-I and high GH or vice versa). Applying the 2014 guidelines in the same group, 16 patients (49%) were in biochemical remission, 7 patients (21%) were not and 10 patients (30%) had discordant results. Thus, by using the most recent criteria for biochemical control, more patients were considered to be in remission, or with discordant results, and fewer patients not in remission (P < 0.05). Conclusion An apparently minor adjustment of the criteria for biochemical control has a significant impact on remission status in patients treated for acromegaly, eventually affecting follow-up and treatment strategies. © 2017 Elsevier Ltd
  •  
25.
  • Olivius, C., et al. (författare)
  • Prevalence and treatment of central hypogonadism and hypoandrogenism in women with hypopituitarism
  • 2018
  • Ingår i: Pituitary. - 1386-341X. ; 21:5, s. 445-453
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose Women with hypopituitarism have increased morbidity and mortality, and hypogonadism has been suggested to be a contributing mechanism. The purpose of this study was to investigate the prevalence of central hypogonadism and hypoandrogenism in women with hypopituitarism at a single Swedish center. Methods All consecutive women (n = 184) who commenced growth hormone (GH) replacement therapy at Sahlgrenska University Hospital in Gothenburg between 1995 and 2015 were included. In accordance with the Endocrine Society Clinical Practice Guidelines, strict criteria, based on menstrual history combined with laboratory measurements, were used to define central hypogonadism. Hypoandrogenism was defined as subnormal levels of dehydroepiandrosterone sulfate and/or androstenedione. Results Central hypogonadism was present in 78% of the women, in 75% of those ≤ 52 years and in 82% of those > 52 years of age. Hypoandrogenism was found in 61% of all the women and in 92% of those with adrenocorticotropic hormone (ACTH) deficiency. The estrogen substitution rate in hypogonadal women ≤ 52 years was lower than the hormonal substitution rate in the other pituitary hormone axes (74% versus 100%, P < 0.001). The use of estrogen substitution tended to decrease between 2000 and 2016. Few women received androgen treatment. Conclusions In this first study of hypogonadism in women with hypopituitarism, using stringent diagnostic criteria for hypogonadism, the prevalence of central hypogonadism and low androgen levels was high and estrogen substitution was insufficient. Further studies are needed to elucidate the importance of hypogonadism and insufficient sex steroid replacement for the increased morbidity in hypopituitary women.
26.
  • Olsson, Daniel S, 1983-, et al. (författare)
  • Excess Mortality in Women and Young Adults With Nonfunctioning Pituitary Adenoma: A Swedish Nationwide Study
  • 2015
  • Ingår i: Journal of Clinical Endocrinology & Metabolism. - 0021-972X. ; 100:7, s. 2651-2658
  • Tidskriftsartikel (refereegranskat)abstract
    • Context: Patients with hypopituitarism of various etiologies have excess mortality. The mortality in patients with nonfunctioning pituitary adenoma (NFPA), regardless of pituitary function, is less well studied. Objective: Our aim was to investigate mortality in patients with NFPA and to examine whether age at diagnosis, gender, tumor treatments, or hormonal deficiencies influence the outcome. Design: NFPA patients were identified and followed up in nationwide health registries in Sweden, 1987-2011. The criteria for identification were tested and validated in a subpopulation of the patients. Patients: A total of 2795 unique patients with NFPA (1502 men, 1293 women) were identified and included in the study. Mean age at diagnosis was 58 years (men, 60 y; women, 56 y) and mean follow-up time was 7 years (range 0-25 y). Main Outcome Measures: Standardized mortality ratios (SMRs) and annual incidence rates were calculated using the Swedish population as reference and presented with 95% confidence intervals. Results: Annual incidence of NFPA was 20.3 (18.8-21.9) cases per 1 million inhabitants. During the observation period, 473 patients died against an expected 431, resulting in an SMR of 1.10 (1.00-1.20). Patients diagnosed at younger than 40 years of age had an increased SMR of 2.68 (1.23-5.09). The SMR for patients with hypopituitarism (n = 1500) was 1.06 (0.94-1.19), and for patients with diabetes insipidus (n = 145), it was 1.71 (1.07-2.58). The SMR was increased in women with NFPA (1.29; 1.11-1.48) but not in men (1.00; 0.88-1.12). Women, but not men, with a diagnosis of hypopituitarism and/or diabetes insipidus also had an increased mortality ratio. SMRs due to cerebrovascular (1.73; 1.34-2.19) and infectious diseases (2.08; 1.17-3.44) were increased, whereas the SMR for malignant tumors was decreased (0.76; 0.61-0.94). Conclusions: This nationwide study of patients with NFPA showed an overall excess mortality in women and in patients with a young age at diagnosis. Increased mortality was seen for cerebrovascular and infectious diseases.
  •  
27.
  • Olsson, Daniel S, 1983-, et al. (författare)
  • Higher incidence of morbidity in women than men with non-functioning pituitary adenoma: a Swedish nationwide study
  • 2016
  • Ingår i: European Journal of Endocrinology. - 0804-4643. ; 175:1, s. 55-61
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: Increased mortality rates are found in women and young adults with non-functioning pituitary adenomas (NFPAs). This nationwide study aimed to investigate the burden of comorbidities in patients with NFPA and to examine whether gender influences the outcome. Design: NFPA patients were identified and followed-up from National Registries in Sweden. It was a nationwide, population-based study. Method: Standardised incidence ratios (SIRs) for comorbidities with 95% confidence intervals (CI). Comorbidities were analysed in all patients, both patients with and without hypopituitarism. Results: Included in the analysis were 2795 patients (1502 men, 1293 women), diagnosed with NFPA between 1987 and 2011. Hypopituitarism was reported in 1500 patients (54%). Mean patient-years at risk per patient was 7 (range 0-25). Both men (SIR 2.2, 95% CI: 1.8-2.5; P < 0.001) and women (2.9, 2.4-3.6; P < 0.001) had a higher incidence of type 2 diabetes mellitus (T2DM) than the general population, with women having a higher incidence compared with men (P = 0.02). The incidence of myocardial infarction was increased in women (1.7, 1.3-2.1; P < 0.001), but not in men. Both men (1.3, 1.1-1.6; P = 0.006) and women (2.3; 1.9-2.8; P < 0.001) had an increased incidence of cerebral infarction, with women having a higher incidence than men (P < 0.001). The incidence of sepsis was increased for both genders. The incidence of fractures was increased in women (1.8, 1.5-1.8; P < 0.001), but not for men. Conclusions: This nationwide study shows excessive morbidity due to T2DM, cerebral infarction and sepsis in all NFPA patients. Women had higher incidence of T2DM, myocardial infarction, cerebral infarction and fracture in comparison to both the general population and to men.
  •  
28.
  •  
29.
  • Olsson, Daniel S, 1983-, et al. (författare)
  • Incidence of malignant tumours in patients with a non-functioning pituitary adenoma.
  • 2017
  • Ingår i: Endocrine-related cancer. - 1479-6821. ; 24:5, s. 227-235
  • Tidskriftsartikel (refereegranskat)abstract
    • Whether patients with non-functioning pituitary adenoma (NFPA) are at increased risk of developing malignant tumours has been sparsely studied and is a matter of debate. In this study, we have investigated the incidence of malignant tumours in a large and unselected group of patients with NFPA. The study was nationwide and included all patients diagnosed with NFPA between 1987-2011 (n=2,795) in Sweden, identified in the National Patient Register. Malignant tumours, occurring after the NFPA diagnosis, were identified in the Swedish Cancer Register between 1987-2014. Standardised incidence ratios (SIRs) for malignant tumours with 95% confidence intervals (CI) were calculated using the Swedish population as reference. In total, 448 malignant tumours were detected in 386 patients with NFPA, as compared to 368 expected malignancies in the general population [SIR 1.22 (95% CI 1.11-1.33)]. The incidence of neoplasms of the brain was increased [SIR 5.83 (95% CI 4.03-8.14)]. When analysing the total incidence of malignancies excluding neoplasms of the brain, the overall SIR was still increased [SIR 1.14 (95% CI 1.03-1.26)]. The incidence of malignant neoplasm of skin other than malignant melanoma [SIR 1.99 (95% CI 1.55-2.52)] and malignant melanoma [SIR 1.62 (95% CI 1.04-2.38)] were increased, whereas the incidence of breast cancer [SIR 0.65 (95% CI 0.42-0.97)] was decreased. The incidence of other types of malignancies did not differ significantly from the expected incidence in the general population. In conclusion, patients with NFPA have an increased over-all risk of developing malignancies. To what extent these findings are due to more frequent medical surveillance, genetic predisposition, or endocrine changes, remains unknown.
  •  
30.
  • Olsson, Daniel S, 1983-, et al. (författare)
  • Life expectancy in patients with pituitary adenoma receiving growth hormone replacement.
  • 2017
  • Ingår i: European journal of endocrinology. - 1479-683X. ; 176:1, s. 67-75
  • Tidskriftsartikel (refereegranskat)abstract
    • Hypopituitarism has been associated with increased mortality. The excess mortality may be due to untreated growth hormone (GH) deficiency but also due to various underlying disorders. We therefore analysed mortality in patients with only one underlying disorder, non-functioning pituitary adenoma (NFPA), with and without GH replacement therapy (GHRT).Patients with NFPA in the western region of Sweden, 1997-2011, were identified through the National Patient Registry and cross-referenced with several National Health Registries. All patient records were reviewed. Standardised mortality ratios (SMRs) with 95% confidence intervals (CIs) were calculated using the general population as reference. Cox-regression models were performed to identify predictors of mortality.A total of 426 NFPA patients with 4599 patient-years were included, of whom 207 had used GHRT and 219 had not received GHRT. Median (range) follow-up in patients with and without GHRT was 12.2 (0-25) and 8.2 (0-27) years, respectively. Other pituitary hormone deficiencies were more frequent in the GHRT group than those in the non-GHRT group. SMR was 0.65 (95% CI, 0.44-0.94; P = 0.018) for the GHRT group and 1.16 (0.94-1.42; P = 0.17) for the non-GHRT group. Direct comparison between the groups showed reduced mortality among those who were GH replaced (P = 0.0063). The SMR for malignant tumours was reduced in the GHRT-group (0.29; 0.08-0.73; P = 0.004) but not in untreated patients.Selection bias explaining some of the results cannot be excluded. However, NFPA patients with GHRT had reduced overall mortality compared with the general population, and death due to malignancy was not increased. This suggests that long-term GHRT is safe in adult patients selected for treatment.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 21-30 av 37
  • Föregående 12[3]4Nästa
Åtkomst
fritt online (3)
Typ av publikation
tidskriftsartikel (34)
forskningsöversikt (2)
konferensbidrag (1)
Typ av innehåll
refereegranskat (35)
övrigt vetenskapligt (2)
Författare/redaktör
Olsson, Daniel S, 19 ... (37)
Johannsson, Gudmundu ... (30)
Ragnarsson, Oskar, 1 ... (17)
Nilsson, Anna G, 196 ... (7)
Bengtsson, Bengt-Åke ... (6)
Bryngelsson, Ing-Lis ... (6)
visa fler...
Skoglund, Thomas, 19 ... (5)
Trimpou, Penelope, 1 ... (5)
Andersson, Eva, 1955 ... (4)
Burman, Pia, (4)
van den Heuvel-Eibri ... (4)
Berinder, Katarina (4)
Wahlberg, Jeanette, (4)
Dahlqvist, Per, (4)
Edén Engström, Britt ... (4)
Esposito, Daniela, (3)
Olsson, Tommy, (3)
Bensing, Sophie, (3)
Wahlberg, J. (3)
Burman, P. (3)
Erfurth, Eva Marie, (3)
Papakokkinou, Eleni, (3)
Petersson, Maria, (3)
Bryngelsson, I. L. (3)
Schwarcz, Erik, (3)
Ragnarsson, O (3)
Berinder, K., (3)
Ekman, Bertil, (3)
Dahlqvist, P. (3)
Høybye, Charlotte, (3)
van der Lely, A. J. (3)
Chantzichristos, Dim ... (3)
Åkerman, Anna-Karin (3)
Bonelli, L. (2)
Olsson, T. (2)
Hellström, Ann, 1959 ... (2)
Bensing, S, (2)
Schwarcz, E. (2)
Bidlingmaier, M. (2)
Johannsson, G (2)
Bryngelsson, IL (2)
Ekman, B (2)
Glad, Camilla A M, 1 ... (2)
Petersson, M, (2)
Engstrom, BE (2)
Hoybye, C, (2)
Buchfelder, M (2)
ERFURTH, EM (2)
Akerman, AK, (2)
Follin, C., (2)
visa färre...
Lärosäte
Göteborgs universitet (37)
Lunds universitet (4)
Karolinska Institutet (3)
Språk
Engelska (37)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (37)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy